NHS Approves New Targeted Treatment for Ovarian Cancer After 20 Years
'Significant breakthrough' as new ovarian cancer treatment approved for NHS use
Evening Standard
Image: Evening Standard
The NHS has approved mirvetuximab soravtansine, a new treatment for women with certain advanced ovarian cancers that are resistant to chemotherapy. This marks the first new drug for ovarian cancer in two decades, providing hope for improved survival and quality of life for patients.
- 01Mirvetuximab soravtansine, also known as Elahere, is now approved for use in the NHS for specific late-stage ovarian, fallopian tube, or peritoneal cancers.
- 02This treatment represents the first new ovarian cancer therapy approved by the NHS in 20 years.
- 03Clinical trials indicate that the drug can extend survival by approximately four months compared to traditional chemotherapy.
- 04Around 400 patients in England are expected to benefit from this new treatment each year.
- 05Patient testimonials highlight significant improvements in quality of life and reduced side effects compared to previous chemotherapy treatments.
Advertisement
In-Article Ad
The National Institute for Health and Care Excellence (NICE) has approved mirvetuximab soravtansine, a new targeted therapy for women suffering from advanced forms of ovarian, fallopian tube, or peritoneal cancers that have become resistant to chemotherapy. This landmark decision marks the first new treatment for ovarian cancer available through the NHS in over 20 years. Experts have noted that the approval provides much-needed options for patients facing limited choices after traditional chemotherapy fails. Clinical trials have shown that this treatment can improve survival rates by an average of four months. NHS England estimates that around 400 patients annually could benefit from this therapy. Patient experiences, such as those shared by Patricia Hill, indicate that mirvetuximab significantly enhances quality of life by reducing side effects typically associated with chemotherapy. The approval is celebrated as a significant breakthrough, offering hope to patients and their families during a challenging time.
Advertisement
In-Article Ad
The approval of mirvetuximab soravtansine provides a new treatment option for women with limited choices due to chemotherapy resistance.
Advertisement
In-Article Ad
Reader Poll
What do you think about the approval of mirvetuximab for ovarian cancer treatment?
Connecting to poll...
More about National Institute for Health and Care Excellence
Read the original article
Visit the source for the complete story.